Differences in the efficacy and safety of eribulin in patients with soft tissue sarcoma by histological subtype and treatment line

Clinical evidence regarding eribulin treatment for patients with soft tissue sarcoma (STS) is limited to those with L-sarcoma (leiomyosarcoma and liposarcoma) who have completed at least two chemotherapies. Whether histological subtypes and treatment lines affect the efficacy and safety of eribulin...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Mol Clin Oncol
Main Authors: Nakano, Kenji, Hayakawa, Keiko, Funauchi, Yuki, Tanizawa, Taisuke, Ae, Keisuke, Matsumoto, Seiichi, Tomomatsu, Junichi, Ono, Makiko, Taira, Shinichiro, Nishizawa, Masatoshi, Wang, Xiaofei, Ohmoto, Akihiro, Sato, Yasuyoshi, Fukuda, Naoki, Urasaki, Tetsuya, Takahashi, Shunji
פורמט: Artigo
שפה:Inglês
יצא לאור: D.A. Spandidos 2021
נושאים:
Articles
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC7709564/
https://ncbi.nlm.nih.gov/pubmed/33282288
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2020.2175
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים